US5882902A - Amino acid conjugate - Google Patents
Amino acid conjugate Download PDFInfo
- Publication number
- US5882902A US5882902A US08/793,876 US79387697A US5882902A US 5882902 A US5882902 A US 5882902A US 79387697 A US79387697 A US 79387697A US 5882902 A US5882902 A US 5882902A
- Authority
- US
- United States
- Prior art keywords
- galnacα
- serine
- threonine
- group
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001413 amino acids Chemical class 0.000 title description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000004473 Threonine Substances 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 17
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 16
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 16
- 239000003054 catalyst Substances 0.000 claims abstract description 12
- 150000008135 α-glycosides Chemical class 0.000 claims abstract description 9
- 150000003355 serines Chemical class 0.000 claims abstract description 7
- 238000005918 transglycosylation reaction Methods 0.000 claims abstract description 6
- 102000002014 alpha-N-Acetylgalactosaminidase Human genes 0.000 claims abstract description 4
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 13
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 13
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 13
- 239000000348 glycosyl donor Substances 0.000 claims description 12
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 9
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 8
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 5
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 5
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims 2
- 102000051366 Glycosyltransferases Human genes 0.000 claims 1
- MQWZJOSNNICZJE-JRTVQGFMSA-N (2r,3s,4s,5s)-5-acetamido-2,3,4-trihydroxy-6-oxohexanoic acid Chemical compound CC(=O)N[C@H](C=O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O MQWZJOSNNICZJE-JRTVQGFMSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 27
- 239000000370 acceptor Substances 0.000 description 15
- 239000007790 solid phase Substances 0.000 description 11
- -1 nucleotide sugars Chemical class 0.000 description 10
- 239000000386 donor Substances 0.000 description 9
- 229960001153 serine Drugs 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229960002898 threonine Drugs 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 125000000962 organic group Chemical group 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000007974 sodium acetate buffer Substances 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000011143 downstream manufacturing Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 4
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 239000001166 ammonium sulphate Substances 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 125000001905 inorganic group Chemical group 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 125000004492 methyl ester group Chemical group 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 125000006501 nitrophenyl group Chemical group 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- 125000003423 D-mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
- 229930182822 D-threonine Natural products 0.000 description 1
- 125000000214 D-xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 125000003686 N-acetyl-D-glucosaminyl group Chemical group C(C)(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1O)O)CO)* 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101150108015 STR6 gene Proteins 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 229940060155 neuac Drugs 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Definitions
- the present invention describes a new method to produce O-glycosylated amino acids, O-glycosylated peptides or derivatives of these.
- the present invention relates to products produced by the above method as well as uses of the resulting products.
- Glycoconjugates contain oligosaccharide chains with up to twenty monosaccharide units and several sequences have been shown to have biological activity e.g. in the binding to different cells, pathogens, toxins, antibodies or other proteins on cell surfaces, in cancer metastasis, in inflammation processes (for example selectin-carbohydrate interactions), binding of white blood cells to the blood vessel wall, as a modifier of the activity, stability and biological activity of proteins, and as immunogenic substances which have potential for vaccination against different diseases.
- An extensive literature has been developed during the last few years in this field and there are several review articles on this type of biology, glycobiology, e.g. in Annual Review of Biochemistry and in current opinion in Structural Biology (see for example volume 3, 1993) incorporated herein by reference.
- glycoconjugate the glycoproteins
- the glycoproteins contain carbohydrate-peptide sequences in which the carbohydrate unit is bound to the peptide or protein chain via mainly three different types of linkages, the O-glycosidic linkage represented by GalNAc ⁇ -OSer and GalNAc ⁇ -OThr, that is the linkage between N-acetyl-D-galactosamine and the hydroxyl group on a L-serine or a L-threonine residue in the peptide of protein chain (several such linkages can be found in a peptide or protein chain depending on the number of serine or threonine units in the molecule), the N-glycosidic linkage between N-acetyl-D-glucosamine and the amide function in asparagine, GlcNAc ⁇ -N-Asn, and the O-glycosidic linkage between galactose or xylose and different hydroxyl group containing amino acids.
- GlcNAc ⁇ -OSer and GlcNAc ⁇ -OThr have been of increased interest, e.g. because of its suggested importance in the DNA-replication in the nucleus of eucaryotic cells.
- linkage are of interest to produce by synthetic methods for fundamental studies and for synthesis of biologically or pharmaceutically active fragments of glycoproteins, for instance for use as vaccines or therapeutics. It is also important to be able to synthesize analogs or derivatives of the structures above for example with other types of sugar and/or configuration, as e.g. mannosamine and the ⁇ - or ⁇ -configuration to modify or to increase the biological activity of the conjugate.
- This invention describes a novel method based on enzymatic synthesis for the preparation of such GalNAc ⁇ -linked compounds.
- Enzymatic synthesis of glycosidic linkages can be carried out with glycosyltransferases (EC 2.4) and with glycosidases (EC 3.2) (see e.g. K. Nilsson, Trends in Biotechnology, 1988, pages 256-264, incorporated herein).
- Glycosyltransferases are in general not available in quantity for large-scale synthesis, have a high acceptor specificity which limits the efficiency with unnatural or modified acceptors and are dependent on nucleotide sugars as glycosyl donors.
- Glycosidases are abundant and have been used for synthesis of non-modified GalNAc ⁇ -Ser e.g. employing the substrates GalNAc and L-serine in high concentration, i.e.
- One purpose of the present invention is to minimize the above mentioned problems in the chemical or enzymatic synthesis of compounds containing the GalNAc ⁇ -Serine and GalNAc ⁇ -Threonine or GlcNAc ⁇ -Serine and GlcNAc ⁇ -Threonine structures.
- the method according to the invention involves at least one reaction where an ⁇ -glycoside of a saccharide which contains GalNAc at the reducing end (D-GalNAc ⁇ -R in the scheme below) is used as glycosyl donor and a derivative of serine or threonine (HSer-R' and HThr-R' in the scheme below) is used as acceptor in a transglycosylation reaction with an endo- or exo-N-acetyl- ⁇ -D-galactosaminidase (GalNAc:ase below) as the catalyst, or, alternatively, where a ⁇ -glycoside of a saccharide which contains GlcNAc at the reducing end (D-GlcNAc ⁇ -R in the scheme below) is used as glycosyl donor and a derivative of serine or threonine (HSer-R' and HThr-R' in the scheme below) is used as acceptor in a transglycosylation reaction with an endo- or ex
- acceptors are L- or D-serine or L- or D-threonine containing compounds or peptides which have been modified in the N-terminal with an organic group (e.g., R--C(O) or R--O--C(O)-- groups, such as for example formyl, acetyl, allyloxycarbonyl (Alloc), t-butyloxycarbonyl (Boc), benzyloxycarbonyl, fenacetyl-, 4-metoxybenzyloxycarbonyl- (Moz-), or 9-fluorenyl methyloxycarbonyl (Fmoc) groups) and which optionally also have been modified in the carboxyl terminal with an alkoxy or aryloxy group (e.g., methoxy, ethyloxy or phenoxy group) forming an ester group at the C-terminal group.
- an organic group e.g., R--C(O) or R--O
- a peptide derivative is acceptor in the reaction according to the invention, the size is preferably di- to penta peptide but even bigger peptide fragments can be glycosylated according to the invention.
- acceptor there can also be used amino acid/peptide derivatives in the D-configuration or a mixture of D and L-configuration.
- the method according to the invention involves at least one reaction where an ⁇ -glycoside of GalNAc (GalNAc ⁇ -R in the scheme below) is used as glycosyl donor and a derivative of Serine or Threonine (HSer-R 1 R 2 and HThr-R 1 R 2 in the scheme below) is used as acceptor in a transglycosylation reaction with exo-N-acetyl- ⁇ -D-galactosaminidase (GalNAc:ase below) as the catalyst (scheme 1): ##STR2## where GalNAc ⁇ -R represents compounds of the type shown below: ##STR3## where R is an aliphatic or aromatic compound (e.g. phenyl or nitrophenyl group): ##STR4##
- GalNAc ⁇ -R represents compounds of the type shown below: ##STR3## where R is an aliphatic or aromatic compound (e.g. phenyl or nitrophenyl group): ##STR4##
- H-Ser-R 1 R 2 and H-Thr-R 1 R 2 in scheme 1 above represent molecules of the type shown below: ##STR5## where R 1 represents a protecting group on the amino group and R 2 represents a protecting group on the carboxyl group.
- R 1 is preferentially selected from acyl or alkyloxy groups such as acetyl, allyloxy and butyloxy groups, respectively, and R 2 is preferentially selected from alkyl or aryl groups such as methyl, ethyl or phenyl groups; optionally, the carboxyl group is unprotected but preferably is protected.
- H-Ser-R 1 R 2 acceptor compounds used in the method according to the invention are thus: ##STR6##
- GalNAc ⁇ -Ser-R 1 R 2 and GalNAc ⁇ -Thr-R 1 R 2 compounds produced according to scheme 1 are thus: ##STR7##
- Typical example of GalNAc ⁇ -Ser-R 1 R 2 compounds produced according to scheme 1 are thus: ##STR8##
- the reactions conditions are not limiting but are selected with regard to the specific reaction and source of enzyme.
- the pH is often selected in the range of 4-8, the reaction temperature in the range -20° to 70° C.
- the predominant solvent can be water with buffer salts (e.g., phosphate, acetate, citrate, carbonate and others known in the art), organic solvent (e.g., acetone, acetonitrile and others known in the art) or mixed solvents, e.g. mixed water-organic solvent or two-phase systems.
- the reaction can be followed by, traditional methods (such as TLC, HPLC, absorbance measurements e.g. of released phenol or nitrophenol from donor), and the reaction is preferentially terminated at the optimal product yield.
- the method for purification is not limiting and may include any of extraction, precipitation, column chromatography (with e.g., silica, Sephadex, active carbon, ion exchanger as solid phase).
- the product can for example be purified by mild acidification (pH 4-5) followed by extraction with suitable organic solvent (e.g. ethyl acetate) to remove unreacted acceptor, followed by for example column chromatography or continued extraction with a less unpolar solvent to remove the product into the organic phase, or evaporation alternatively freeze drying of the water phase followed by extraction with for example methanol column chromatography of the methanol phase.
- suitable organic solvent e.g. ethyl acetate
- the enzyme may be used in immobilized, cross-linked or in soluble form and in a more or less purified form.
- the enzyme may be used adsorbed to a solid phase (e.g. a glass, silica, polystyrene, another plastic, a polysaccharide (e.g. cellulose or agarose)) or enriched in a water phase in a two-phase system.
- a solid phase e.g. a glass, silica, polystyrene, another plastic, a polysaccharide (e.g. cellulose or agarose)
- examples are the use of enzyme adsorbed to e.g. celite or XAD R resins.
- the latter may be especially useful in the cases when organic solvents (acetone, acetonitrile, tetrahydrofurane) are used as cosolvents (in high concentrations e.g. >70%) or in two-phase systems.
- the enzymes may be obtained from natural sources or from
- the method according to the invention also involves the use of chemical or enzymatic methods for specific modification of the product with organic or inorganic groups or for the specific removal of protection groups on the amino and/or carboxyl groups.
- protection groups are removed according to standard chemical techniques known to those skilled in the art.
- enzymes can be used.
- lipase or protease may be used according to the invention for removal of the R 2 group producing product with a free carboxyl group, e.g. reaction of compounds III and IV above with lipase gives V and VI below: ##STR9##
- Such compounds are useful for binding to other molecules via the carboxyl group, e.g. for preparation of glycopeptides using peptide forming enzymes such a proteases or using standard chemical techniques for peptide formation (such as carbodiimide reagents).
- the methyl ester containing product III 350 mg was dissolved in sodium phosphate buffer (pH 7, 50 mM, 14 ml) and 700 mg of the lipase (Boehringer, Chirazyme L-7; 2 g) was added. The reaction was allowed to proceed at 45° C. for 5 days and the product purified by column chromatography (Sephadex G10 and silica) which gave 164 mg of freeze-dried product).
- the amino group of the product of scheme 1 may also be deprotected and then used for various purposes such as in various peptide forming reactions employing peptide forming enzymes or chemical methods.
- chemical methods are used for peptide formation the hydroxyl groups of the sugar may first be protected e.g. with acyl groups. See for example Houben-Weyl, Bd15/1maschinee 3/79, 14 and especially Synthetic Peptide, G. A. Grant, Editor, W. H. Freeman and Company, New York, 1992 for reviews on peptides and glycopeptides).
- GalNAc ⁇ -Ser or GalNAc ⁇ -Thr containing compounds thus prepared are useful for e.g. binding to solid phases equipped with a covalently bound spacer molecule, e.g. a covalently bound alkyl amine residue such as hexylamine or covalently bound alkyl. carboxyl acid such as covalently bound mercaptopropionic acid, e.g. as bound to soluble or insoluble polymers or to other surfaces, to which compounds e.g.
- a covalently bound spacer molecule e.g. a covalently bound alkyl amine residue such as hexylamine or covalently bound alkyl.
- carboxyl acid such as covalently bound mercaptopropionic acid, e.g. as bound to soluble or insoluble polymers or to other surfaces, to which compounds e.g.
- the GalNAc ⁇ -Ser or the GalNAc ⁇ -Thr compound is first modified in solution with the spacer molecule and the resulting spacer modified compound is then used for binding to the solid phase (or alternatively to a protein, peptide, lipid, polyethylene glycol or other organic molecule of interest for the specific application).
- the solid phase thus prepared containing bound GalNAc ⁇ -Ser or GalNAc ⁇ -Thr containing residues can be used for analytical, down stream processing (affinity chromatography) or for (solid phase) synthetic purposes.
- Example of solid phases are those based on synthetic or naturally occurring polymers, such as polystyrene, polyacrylamine, copolymers, etc, cellulose, agarose, etc. commonly used in analytical or down stream processing applications, metal coated surfaces, such as gold or silver coated materials and colloidal gold particles. Methods for binding of molecules to such surfaces are well documented in the literature, (see e.g. Method in Enzymology, vol. 44, 104, 134-137 and in PCT/SE94/00343) and are straightforward to apply in analytical, down stream processing or solid phase synthetic applications.
- the GalNAc ⁇ -Ser or GalNAc ⁇ -Thr containing compounds obtained in the scheme 1 and/or after immobilization with the methods above are useful e.g. as acceptors in enzymatic reactions employing either glycosyltransferases or glycosidases as catalysts.
- a glycosidase specific for the glycosyl donor Don-R where Don symbolizes a sugar unit and R symbolizes an aglycon such as a nitrophenyl group, which is bound in ⁇ - or ⁇ - configuration to the sugar group
- Don-GalNAc ⁇ -Ser-R" or Don-GalNAc ⁇ -Thr-R" where R" symbolize either -H, i.e. no modification on the serine or threonine residue, or a modification by an amino acid, peptide or other organic group, on at least one of the amino or carboxyl groups: ##STR10##
- Don above may be selected from the group consisting of compounds containing at lest one L-fucosyl, D-glucosyl-, D-galatosyl-, D-mannosyl, D-xylosyl, N-acetyl-D-glucosaminyl, N-acetyl-D-galactosylaminyl or sialyl group.
- the glycosidase may be selected from the group of exo- or endoglycosidases belonging to the EC 3.2. class of hydrolases.
- ⁇ -galactosidase preparation obtained from e.g. bovine testes
- lactose or Gal ⁇ -PNP lactose
- Gal ⁇ -PNP p-nitrophenyl
- glycosyltransferases a nucleotide sugar, Don-N, is used as donor and GalNAc ⁇ -Ser-R" or GalNAc ⁇ -Thr-R" as acceptor.
- An example is the use of sialytransferase to produce NeuAc ⁇ 2-6GalNAc ⁇ -Ser-R" or NeuAc ⁇ 2-6GalNAc ⁇ -Thr-R" employing CMP-NeuAc as donor.
- Glycosyltranferases are also of interest for use with solid phase bound GalNAc ⁇ -Ser-R" or GalNAc ⁇ -Thr-R".
- disaccharide products can be applied for analytical down-stream processing, or (solid phase) chemical or enzymatic synthetic purposes as described above.
- the products are also of interest for therapeutic applications, for modification of organic compounds of therapeutic interest, or of interest as food or cosmetical product additives to obtain products with novel properties.
- the yield of product is often in the range of 10-50% as calculated on the donor.
- the reaction can be carried out for e.g. 15 minutes up to 24 hours or more.
- the reaction time is determined by the reaction rate and is stopped when the donor is consumed (if this is used as the limiting substrate) or preferably when the maximum amount of product has been formed (as determined e.g. by HPLC).
- Non-limiting examples of reaction according to scheme 1 above is given below.
- GalNAc ⁇ -PNP (170 mM) and N-Alloc-L-Ser-OMe (0.9M) suspended in sodium acetate buffer (pH 4.4) were reacted at 45° C. for 4 hours with 30 mg (per 0.5 ml reaction volume) of freeze-dried GalNAc ⁇ -ase as catalyst (prepared as described above). At this time the reaction was stopped indicating formation of 40 mM product (HPLC; ca 23% molar yield as calculated on reacted donor).
- GalNAc ⁇ -PNP (170 mM) and N-acetyl-L-Ser-OMe (2M) suspended in sodium acetate buffer (pH 4.4) were reacted as described above at 45° C. with freeze-dried GalNAc ⁇ -ase as catalyst (prepared as described above) until ca 70 mM product was obtained (HPLC; ca 40% molar yield as calculated on reacted donor).
- GalNAc ⁇ -PNP (170 mM) and N-acetyl-L-Thr-OMe (0.9M) suspended in sodium acetate buffer (pH 4.4) were reacted as described above at 45° C. with freeze-dried GalNAc ⁇ -ase as catalyst (prepared as described above) until ca 49 mM product as obtained (HPLC; ca 29% molar yield as calculated on reacted donor).
Landscapes
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Peptides Or Proteins (AREA)
- Polyamides (AREA)
Abstract
Description
Claims (9)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9403011A SE9403011D0 (en) | 1994-09-06 | 1994-09-06 | Aminosockerkonjugat |
| SE9403011 | 1994-09-06 | ||
| SE9502159A SE9502159D0 (en) | 1995-06-10 | 1995-06-10 | Aminoacid conjugate |
| SE9502159 | 1995-06-10 | ||
| PCT/IB1995/000740 WO1996007753A1 (en) | 1994-09-06 | 1995-09-06 | Amino acid conjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5882902A true US5882902A (en) | 1999-03-16 |
Family
ID=26662133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/793,876 Expired - Fee Related US5882902A (en) | 1994-09-06 | 1995-09-06 | Amino acid conjugate |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5882902A (en) |
| EP (1) | EP0779932B1 (en) |
| AT (1) | ATE195147T1 (en) |
| AU (1) | AU3264195A (en) |
| DE (1) | DE69518246T2 (en) |
| WO (1) | WO1996007753A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050053900A1 (en) * | 2003-09-05 | 2005-03-10 | Steven Kaufmann | Method of teaching a foreign language to a student providing measurement in a context based learning system |
| US20070280987A1 (en) * | 2006-05-30 | 2007-12-06 | Helmus Michael N | Bioactive polymers for imparting bioactive character to hydrophobic medical article surfaces |
| US9051593B2 (en) | 2009-12-21 | 2015-06-09 | Trustees Of Dartmouth College | Recombinant prokaryotes and use thereof for production of O-glycosylated proteins |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9904695D0 (en) * | 1999-03-01 | 1999-04-21 | Imp Cancer Res Tech | Peptide |
| JP2002176998A (en) * | 2000-12-15 | 2002-06-25 | Meiji Milk Prod Co Ltd | Mucin-type glycopeptide and glycoprotein production method |
| US7598354B2 (en) * | 2002-08-01 | 2009-10-06 | National Research Council Of Canada | Campylobacter glycans and glycopeptides |
| MXPA06012676A (en) | 2004-05-04 | 2007-04-02 | Novo Nordisk Healthcare Ag | O-linked glycoforms of polypeptides and method to manufacture them. |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583042A (en) * | 1990-04-16 | 1996-12-10 | Neose Pharmaceuticals, Inc. | Apparatus for the synthesis of saccharide compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE451849B (en) * | 1985-12-11 | 1987-11-02 | Svenska Sockerfabriks Ab | VIEW TO SYNTHETIZE GYCLOSIDIC BINDINGS AND USE OF THIS RECEIVED PRODUCTS |
| DE4013077A1 (en) * | 1990-04-25 | 1991-10-31 | Hoechst Ag | METHOD FOR GLYCOSIDASE-CATALYZED SYNTHESIS OF GLYCO-CONJUGATES |
| SE9102292L (en) * | 1991-08-06 | 1993-02-07 | Kurt G I Nilsson | ENZYMATIC METHOD |
| EP0551107A2 (en) * | 1992-01-09 | 1993-07-14 | Hoechst Aktiengesellschaft | Method for a beta-galactosidase catalyzed transglycosilation with non-physiological glycosyl-donors |
| SE9304316D0 (en) * | 1993-12-24 | 1993-12-24 | Kurt Nilsson | Amino acid conjugates |
-
1995
- 1995-09-06 AU AU32641/95A patent/AU3264195A/en not_active Abandoned
- 1995-09-06 US US08/793,876 patent/US5882902A/en not_active Expired - Fee Related
- 1995-09-06 DE DE69518246T patent/DE69518246T2/en not_active Expired - Lifetime
- 1995-09-06 EP EP95929186A patent/EP0779932B1/en not_active Expired - Lifetime
- 1995-09-06 AT AT95929186T patent/ATE195147T1/en not_active IP Right Cessation
- 1995-09-06 WO PCT/IB1995/000740 patent/WO1996007753A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583042A (en) * | 1990-04-16 | 1996-12-10 | Neose Pharmaceuticals, Inc. | Apparatus for the synthesis of saccharide compositions |
Non-Patent Citations (1)
| Title |
|---|
| APS Abstract JP409037790A (Feb. 10, 1997) Ajisaka et al. * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050053900A1 (en) * | 2003-09-05 | 2005-03-10 | Steven Kaufmann | Method of teaching a foreign language to a student providing measurement in a context based learning system |
| US20070280987A1 (en) * | 2006-05-30 | 2007-12-06 | Helmus Michael N | Bioactive polymers for imparting bioactive character to hydrophobic medical article surfaces |
| US7625552B2 (en) * | 2006-05-30 | 2009-12-01 | Boston Scientific Scimed, Inc. | Bioactive polymers for imparting bioactive character to hydrophobic medical article surfaces |
| US9051593B2 (en) | 2009-12-21 | 2015-06-09 | Trustees Of Dartmouth College | Recombinant prokaryotes and use thereof for production of O-glycosylated proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69518246T2 (en) | 2000-12-21 |
| AU3264195A (en) | 1996-03-27 |
| EP0779932A1 (en) | 1997-06-25 |
| ATE195147T1 (en) | 2000-08-15 |
| DE69518246D1 (en) | 2000-09-07 |
| WO1996007753A1 (en) | 1996-03-14 |
| EP0779932B1 (en) | 2000-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nilsson | Enzymatic synthesis of oligosaccharides | |
| Spiro et al. | Structure of the O-glycosidically linked carbohydrate units of fetuin | |
| US5659015A (en) | Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof | |
| US5856143A (en) | N-containing saccharides and method for the synthesis of N-containing saccharides from amino-deoxy-disaccharides and amino-deoxy-oligosaccharides | |
| US7955819B2 (en) | Process for producing sugar chain asparagine derivative | |
| Nilsson | Synthesis with glycosidases | |
| US5599694A (en) | Process for producing an oligosaccharide compound by using glycosidases from a mollusc | |
| USRE39245E1 (en) | Galactopyranosides and their use | |
| US5882902A (en) | Amino acid conjugate | |
| Fukuda et al. | Isolation and characterization of alkali-labile oligosaccharide units from horse glycophorin | |
| US6653109B1 (en) | Method of producing derivatives of lactosamine | |
| EP0736101A1 (en) | Enzymatic method for synthesis of o-glycosylated amino acid or peptide or derivatives thereof | |
| EP0839210B1 (en) | Method of producing derivatives of glc-beta 1-4glc-n-acetyl | |
| US6183994B1 (en) | N-containing saccharides and method for the synthesis of N-containing saccharides from amino-deoxy-disaccharides and amino-deoxy-oligosaccharides | |
| Nilsson et al. | Synthesis of glycosylated serine and threonine derivatives employing glycosidases | |
| Hayashi et al. | Action of lysozyme on oligosaccharides from peptidoglycan N-unacetylated at glucosamine residues | |
| US20240409571A1 (en) | Chemoenzymatic synthesis of n-acetylated gangliosides and glycosphingosines | |
| US5936075A (en) | Amino-deoxy-disaccharides and amino-deoxy-oligosaccharides | |
| Li et al. | [14] Ceramide glycanase from the leech Macrobdella decora and oligosaccharide-transferring activity | |
| JP3732871B2 (en) | Method for producing complex carbohydrate | |
| Rudick | Mannosyl transfer by membranes of Aspergillus niger: mannosylation of endogenous acceptors and partial analysis of the products | |
| Valenteković et al. | Synthesis, properties, and reactions of α-and β-D-glucopyranosyl esters of some tripeptides | |
| Michaels | IDENTIFICATION AND MODIFICATION OF THE CARBOHYDRATE RESIDUES IN FUSARIUM TRICINCTUM ASPARAGINASE. | |
| JPH1045788A (en) | Production of new glycoconjugate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: BIOFLEXIN AB, A CORPORATION OF SWEDEN, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NILSSON, KURT;REEL/FRAME:009030/0443 Effective date: 19970505 |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| AS | Assignment |
Owner name: GLYCOREX TRANSPLANTATION AB (PUBL), SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOFLEXIN AB;REEL/FRAME:023409/0621 Effective date: 20091012 |
|
| FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20110316 |